Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17768973 | 0.93 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2BSMN1; SMN2 | |
| SCHEMBL17768637 | 0.88 | ADORA2A (0.46) | ADORA2AADORA1ADORA3ADORA2BGRM5 | |
| SCHEMBL17768924 | 0.87 | ADORA2A (0.57) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17768824 | 0.84 | ADORA2A (0.43) | ADORA2AADORA1ADORA3ADORA2BSMN1; SMN2 | |
| SCHEMBL17769005 | 0.83 | ROS1 (0.44) | ADORA2AADORA1MALT1 | |
| SCHEMBL17768814 | 0.83 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2BMALT1 | |
| SCHEMBL17768853 | 0.81 | PRNP (0.49) | ADORA2AADORA1SMN1; SMN2GRM5 | |
| SCHEMBL17769018 | 0.80 | ADORA2A (0.50) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17769154 | 0.79 | HPGD (0.50) | ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL17768668 | 0.79 | CNR1 (0.49) | ADORA2AADORA1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | claimed |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | claimed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3220910-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | Merck Sharp & Dohme Corp. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081290-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081290-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.